fda tirzepatide injection shortage resolved october 2 2024 says years-long is resolved, will give limited leeway to compounders FDA backtracks over Eli Lilly

Update on FDAs ongoing evaluation of reports of suicidal thoughts-or-actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity

Since tirzepatide affects GLP-1 receptors in the brain, its possible that this could lead to headaches, though this is less common

November 2025: When people start taking GLP-1 drugs like Zepbound, they may experience vision-related side effects

The financial incentive is enormous

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental condition that affects how the brain regulates attention, impulses, and activity levels

Tirzepatide may be considered for patients who may benefit from dual GIP and GLP-1 activity